AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular Dystrophy gene therapy
28-Sep-2010 -
Amsterdam Molecular Therapeutics (AMT) Holding N.V. announced that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines ...
Amsterdam Molecular Therapeutics
clinical trials
Duchenne muscular dystrophy
+9